BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19804285)

  • 1. Potential of adiponectin as a cardioprotective agent.
    Shibata R; Ouchi N; Walsh K; Murohara T
    Future Cardiol; 2007 Nov; 3(6):647-56. PubMed ID: 19804285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioprotection by adiponectin.
    Ouchi N; Shibata R; Walsh K
    Trends Cardiovasc Med; 2006 Jul; 16(5):141-6. PubMed ID: 16781946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adiponectin actions in the cardiovascular system.
    Hopkins TA; Ouchi N; Shibata R; Walsh K
    Cardiovasc Res; 2007 Apr; 74(1):11-8. PubMed ID: 17140553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue.
    Yoneda M; Iwasaki T; Fujita K; Kirikoshi H; Inamori M; Nozaki Y; Maeyama S; Wada K; Saito S; Terauchi Y; Nakajima A
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S15-21. PubMed ID: 17331160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
    Ferdinandy P; Schulz R; Baxter GF
    Pharmacol Rev; 2007 Dec; 59(4):418-58. PubMed ID: 18048761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age and obesity-associated changes in the expression and activation of components of the AMPK signaling pathway in human right atrial tissue.
    Niemann B; Pan R; Teschner M; Boening A; Silber RE; Rohrbach S
    Exp Gerontol; 2013 Jan; 48(1):55-63. PubMed ID: 22546364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adiponectin: anti-inflammatory and cardioprotective effects.
    Villarreal-Molina MT; Antuna-Puente B
    Biochimie; 2012 Oct; 94(10):2143-9. PubMed ID: 22796520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.
    Kadowaki T; Yamauchi T; Kubota N; Hara K; Ueki K; Tobe K
    J Clin Invest; 2006 Jul; 116(7):1784-92. PubMed ID: 16823476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adiponectin and cardiovascular disease: response to therapeutic interventions.
    Han SH; Quon MJ; Kim JA; Koh KK
    J Am Coll Cardiol; 2007 Feb; 49(5):531-8. PubMed ID: 17276175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
    Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
    Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting adiponectin for cardioprotection.
    Ouchi N; Shibata R; Walsh K
    Expert Opin Ther Targets; 2006 Aug; 10(4):573-81. PubMed ID: 16848693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adiponectin and interleukin-6 in inflammation-associated disease.
    Li L; Wu LL
    Vitam Horm; 2012; 90():375-95. PubMed ID: 23017723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of adiponectin in the development of high fat diet-induced metabolic abnormalities in mice.
    Hecker PA; O'Shea KM; Galvao TF; Brown BH; Stanley WC
    Horm Metab Res; 2011 Feb; 43(2):100-5. PubMed ID: 21165812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adiponectin and hypertension.
    Ohashi K; Ouchi N; Matsuzawa Y
    Am J Hypertens; 2011 Mar; 24(3):263-9. PubMed ID: 20930707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adiponectin and vulnerable atherosclerotic plaques.
    Barseghian A; Gawande D; Bajaj M
    J Am Coll Cardiol; 2011 Feb; 57(7):761-70. PubMed ID: 21310310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adiponectin--its role in metabolism and beyond.
    Stefan N; Stumvoll M
    Horm Metab Res; 2002 Sep; 34(9):469-74. PubMed ID: 12384822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of blood adipose tissue hormones concentration--adiponectin, resistin and leptin in the prediction of major adverse cardiac events (MACE) in 1-year follow-up after primary percutaneous coronary intervention in ST-segment elevation acute myocardial infarction.
    Piestrzeniewicz K; Luczak K; Goch JH
    Neuro Endocrinol Lett; 2008 Aug; 29(4):581-8. PubMed ID: 18766137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convergence of adipocyte hypertrophy, telomere shortening and hypoadiponectinemia in obese subjects and in patients with type 2 diabetes.
    Monickaraj F; Gokulakrishnan K; Prabu P; Sathishkumar C; Anjana RM; Rajkumar JS; Mohan V; Balasubramanyam M
    Clin Biochem; 2012 Nov; 45(16-17):1432-8. PubMed ID: 22827962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adipokines: adiponectin, leptin, resistin and coronary heart disease risk].
    Kopff B; Jegier A
    Przegl Lek; 2005; 62 Suppl 3():69-72. PubMed ID: 16521924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [From myocardial hypertrophy to heart failure: role of the interstitium].
    Barsotti A; Dini FL; Nardini V; Di Muzio M; Gallina S; Di Napoli P; Calafiore AM; Trevi G
    Cardiologia; 1993 Dec; 38(12 Suppl 1):67-77. PubMed ID: 8020050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.